Publications by authors named "Pierre Squifflet"

Claim this Profile
R
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, Marion T van Mackelenbergh, Michael Untch

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E Geyer, Pierre Squifflet

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Nehal J Lakhani, Laura Q M Chow, Justin F Gainor, Patricia LoRusso, Keun-Wook Lee, Pierre Squifflet

Lancet Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.
Elisabeth Coart, Stefan Suciu, Pierre Squifflet, Everardo D Saad, Andriy Moshyk

Eur J Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Everardo D Saad, Pierre Squifflet, Tomasz Burzykowski, Emmanuel Quinaux, Suzette Delaloge

Lancet Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of data errors on the outcome of randomized clinical trials.
Marc Buyse, Pierre Squifflet, Elisabeth Coart, Emmanuel Quinaux, Cornelis Ja Punt

Clin Trials· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
Pierre Squifflet, Stefan Michiels, David Siegel, Ravi Vij, Sundar Jagannath

Clin Lymphoma Myeloma Leuk· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.
Silvy Laporte, Pierre Squifflet, Noémie Baroux, Frank Fossella, Vassilis Georgoulias

BMJ Open· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
Marc Buyse, Stefan Michiels, Pierre Squifflet, Kathryn J Lucchesi, Kristoffer Hellstrand

Haematologica· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
Marc Buyse, Pierre Squifflet, Beverly J Lange, Todd A Alonzo, Richard A Larson

Blood· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia.
Marc Buyse, Pierre Squifflet, Kathryn J Lucchesi, Mats L Brune, Sylvie Castaigne

Trials· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis